Market Research Logo

Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

The global market for cancer vaccines was valued at nearly $4.2 billion and $4.0 billion in 2014 and 2015, respectively. This market is expected to decline from nearly $3.5 billion in 2016 to $3.4 billion in 2021 at a compound annual growth rate (CAGR) of -0.4% for 2016-2021.

This report provides:
An overview of the global markets and technologies for cancer vaccines.
Analyses of global market trends, with data from 2014 and 2015, estimates for 2016, and projections of CAGRs through 2021.
Coverage of the cancer vaccines arena including diverse therapeutic platform technologies, immune-stimulating agents and approved vaccines for cancer.
Examination of the governmental and regulatory environment and how its effecting the market.
Information on new developments including products in Phase I-IV clinical trials, as well as new technologies.
Analysis of the market's dynamics, specifically growth and restriction factors, acquisitions and collaborations, and a look at the cancer vaccine market's current achievements and future challenges.
Relevant patent analysis, presented by year and by vaccine type.
Profiles of major players in the industry.


SCOPE OF THE STUDY

The scope of this study entails the global market of cancer vaccines. The report covers the total market of cancer vaccines, which includes two main areas of applications, prophylactic vaccines and therapeutic vaccines. Human papillomavirus (HPV) vaccines and hepatitis B vaccines that indirectly act against cancer are also included in the report.

The report also covers the global market of cancer vaccines by application in various cancer types such as prostate, liver, cervical and others such as lung and urinary bladder. It is discussed from both a commercial perspective and that of a research and development (R&D) perspective.

BCC Research analyzes each market and its application, regulatory environment, new products and advancements, market projections and market shares. Sales data for the global and regional markets were corroborated for the present and forecasted values via statistical analysis and geographically sales are broken down into North America, Europe and emerging markets. The emerging market covers countries such as India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, and Canada among others.

Analysis of patents, clinical trials, innovations and opportunities the latest trends in the cancer vaccine market and comprehensive profiles of companies that lead the cancer vaccine industry are also discussed.

CHAPTER 1 INTRODUCTION
STUDY OBJECTIVES
REASONS FOR DOING THIS STUDY
CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ANALYSTS' CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 EXECUTIVE SUMMARY
SUMMARY TABLE GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
SUMMARY FIGURE GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
CHAPTER 3 OVERVIEW
DEFINITIONS
HISTORY OF CANCER AND ITS MANAGEMENT
TABLE 1 HISTORY OF CANCER AND ITS MANAGEMENT
CAUSES OF CANCER
GENETIC FACTORS
LIFESTYLE FACTORS
ENVIRONMENTAL FACTORS
TYPES OF CANCER-CAUSING GENES
IMMUNE SYSTEM AND CANCER
CLASSIFICATION OF CANCER
CANCER PREVENTION
TYPES OF CANCER TREATMENT
SURGERY
RADIATION THERAPY
CHEMOTHERAPY
IMMUNOTHERAPY
TARGETED THERAPY
CANCER VACCINES
LIVER CANCER
PROSTATE CANCER
Radical Retropubic Prostatectomy
Laparoscopic Prostatectomy
Radical Perineal Prostatectomy
Transurethral Resection of the Prostate
CERVICAL CANCER
CANCER VACCINES PLATFORM
Tumor Cell Vaccines
Cancer Stem Cell Vaccines
Peptide/Protein Vaccines
Antigen Vaccines
Anti-idiotype Vaccines
Heat Shock Protein Vaccines
DNA and Vector-Based Vaccines
CHAPTER 4 REGULATORY ASPECTS
REGULATORY HISTORY OF APPROVED CANCER VACCINES
TABLE 2 REGULATORY APPROVALS OF CANCER VACCINES, JUNE 2006 TO OCT. 2015
RECALLS
TABLE 3 PRODUCT RECALLS, DECEMBER 2013
ORPHAN DRUG DESIGNATION
TABLE 4 SIGNIFICANT ORPHAN DRUG DESIGNATIONS APPROVED, JAN. 2012 TO JUNE 2016
FAST TRACK DESIGNATIONS
CHAPTER 5 NEW DEVELOPMENTS
PROSTATE CANCER
TABLE 5 CLINICAL TRIALS ON PROSTATE CANCER VACCINES, AS OF JUNE 2016 (NO.)
TABLE 6 SIGNIFICANT PROSTATE CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
BREAST CANCER
TABLE 7 CLINICAL TRIALS ON BREAST CANCER VACCINES, AS OF JUNE 2016 (NO.)
TABLE 8 SIGNIFICANT BREAST CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
CERVICAL CANCER
TABLE 9 CLINICAL TRIALS ON CERVICAL CANCER VACCINES, AS OF JUNE 2016 (NO.)
TABLE 10 SIGNIFICANT CERVICAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
LIVER CANCER
TABLE 11 CLINICAL TRIALS ON LIVER CANCER VACCINES, AS OF JUNE 2016 (NO.)
TABLE 12 SIGNIFICANT LIVER CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
LUNG CANCER
TABLE 13 CLINICAL TRIALS ON LUNG CANCER VACCINES, AS OF JUNE 2016 (NO.)
TABLE 14 SIGNIFICANT VACCINES IN DEVELOPMENT FOR LUNG CANCER, AS OF JUNE 2016
STOMACH CANCER
TABLE 15 CLINICAL TRIALS ON STOMACH CANCER VACCINES, AS OF JUNE 2016 (NO.)
TABLE 16 SIGNIFICANT STOMACH CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
COLORECTAL CANCER
TABLE 17 CLINICAL TRIALS ON COLORECTAL CANCER VACCINES, AS OF JUNE 2016 (NO.)
TABLE 18 SIGNIFICANT COLORECTAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
ESOPHAGEAL CANCER
TABLE 19 CLINICAL TRIALS ON ESOPHAGEAL CANCER VACCINES, AS OF JUNE 2016 (NO.)
TABLE 20 SIGNIFICANT ESOPHAGEAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016
CHAPTER 6 MARKET ANALYSIS
MARKET BY TYPE
MARKET OVERVIEW
MARKET REVENUE
TABLE 21 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, THROUGH 2021 ($ MILLIONS)
FIGURE 1 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, 2014-2021 ($ MILLIONS)
MARKET SHARES
TABLE 22 MARKET SHARE OF CANCER VACCINES BY TYPE, 2015 (%)
FIGURE 2 MARKET SHARE OF CANCER VACCINES BY TYPE, 2015 (%)
MARKET BY REGION
MARKET OVERVIEW
MARKET REVENUE
TABLE 23 GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 3 GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
THERAPEUTIC VACCINES
Market Overview
Market Revenue
TABLE 24 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 4 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
Market Share
TABLE 25 MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2015 (%)
FIGURE 5 MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2015 (%)
PROPHYLACTIC VACCINES
Market Overview
Market Revenue
TABLE 26 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 6 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
Market Share
TABLE 27 PROPHYLACTIC VACCINE MARKET SHARES BY REGION, 2015 (%)
FIGURE 7 PROPHYLACTIC VACCINE MARKET SHARES BY REGION, 2015 (%)
CHAPTER 7 INDUSTRY STRUCTURE
PROPHYLACTIC CANCER VACCINES
MARKET LEADERS
TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF PROPHYLACTIC CANCER VACCINES, 2015
MARKET SHARE
TABLE 29 MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2015 (%)
FIGURE 8 MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2015 (%)
THERAPEUTIC CANCER VACCINES
MARKET LEADER
TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC CANCER VACCINES, 2015
MARKET SHARE
TABLE 31 MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2015 (%)
FIGURE 9 MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2015 (%)
CHAPTER 8 MARKET BY APPLICATION
GLOBAL MARKET FOR CANCER VACCINES BY APPLICATION IN VARIOUS
CANCERS
MARKET REVENUES
TABLE 32 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, THROUGH 2021 ($ MILLIONS)
FIGURE 10 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, 2014-2021 ($ MILLIONS)
MARKET SHARE
TABLE 33 CANCER VACCINE MARKET SHARES BY TYPE OF CANCER, 2015 (%)
FIGURE 11 CANCER VACCINE MARKET SHARES BY TYPE OF CANCER, 2015 (%)
PROSTATE CANCER
MARKET OVERVIEW
MARKET REVENUE
TABLE 24 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 12 GLOBAL MARKET FOR PROSTATE CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
LIVER CANCER
MARKET OVERVIEW
MARKET REVENUES
TABLE 35 GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 13 GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
CERVICAL CANCER VACCINES
MARKET OVERVIEW
MARKET REVENUES
TABLE 36 GLOBAL MARKET FOR CERVICAL CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 14 GLOBAL MARKET FOR CERVICAL CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
OTHER VACCINES FOR CANCER
MARKET OVERVIEW
MARKET REVENUE
TABLE 37 GLOBAL MARKET FOR OTHER CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 15 GLOBAL MARKET FOR OTHER CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS)
CHAPTER 9 PATENT ANALYSIS
PATENTS BY YEAR
TABLE 38 U.S. PATENTS BY YEAR, 2012 TO JUNE 2016 (NO.)
FIGURE 16 U.S. PATENTS BY YEAR, 2012 TO JUNE 2016 (NO.)
PATENTS BY TYPE/CATEGORY
TABLE 39 U.S. PATENTS BY CATEGORY, 2012 TO JUNE 2016 (NO.)
FIGURE 17 U.S. PATENTS BY CATEGORY, 2012 TO JUNE 2016 (NO.)
PATENTS BY COMPANY
TABLE 40 U.S. PATENTS BY COMPANY, 2012 TO JUNE 2016 (NO.)
PATENTS BY COUNTRY
TABLE 41 U.S. PATENTS BY COUNTRY, 2012 TO JUNE 2016 (NO.)
TABLE 42 U.S. PATENT SHARES BY COUNTRY, 2012 TO JUNE 2016 (NO./%)
FIGURE 18 U.S. PATENT SHARES BY COUNTRY, 2012 TO JUNE 2016 (%)
PATENTS BY ASSIGNEE TYPE
TABLE 43 U.S. PATENTS BY ASSIGNEE TYPE, JAN. 2012 TO JUNE 2016 (NO.)
FIGURE 19 U.S. PATENTS BY ASSIGNEE TYPE, JAN. 2012 TO JUNE 2016 (NO.)
CHAPTER 10 CURRENT SITUATION
FACTORS AFFECTING CANCER VACCINES
INCREASING PREVALENCE OF CANCER
AGING POPULATION
LIFESTYLE CHANGES
APPROVALS FOR ADDITIONAL INDICATIONS
COMPETITION
INCREASED FUNDING
MANUFACTURERS' STRATEGIES
CHALLENGES IN CANCER VACCINE MARKET
CHAPTER 11 COMPANY PROFILES
ADAMIS PHARMACEUTICALS CORP.
ADURO BIOTECH INC.
ADVANTAGENE INC.
ADVAXIS INC.
ALPHAVAX INC.
ALTOR BIOSCIENCE CORP.
ANTIGEN EXPRESS INC.
BAVARIAN NORDIC A/S
BELLICUM PHARMACEUTICALS
BIOVEST INTERNATIONAL INC.
CASCADIAN THERAPEUTICS INC.
CELLDEX THERAPEUTICS
CUREVAC AG
DENDREON CORP.
EMD SERONO
GALENA BIOPHARMA INC.
GENEXINE INC.
GLAXOSMITHKLINE
GLOBEIMMUNE INC.
GRADALIS
HEAT BIOLOGICS INC.
IMMUNE CELL THERAPY INC. (ICT)
IMMUNICUM AB
IMMUNOVATIVE THERAPIES LTD.
INOVIO PHARMACEUTICALS
ISA PHARMACEUTICALS B.V.
GEMVAX & KAEL CO. LTD.
MERCK &CO.
NEWLINK GENETICS CORP.
NOVARX CORP.
ONCOVIR INC.
OXFORD BIOMEDICA PLC
SOTIO AS
UBIVAC LLC
VICAL INC.
VACCINOGEN INC.
VAXON BIOTECH
CHAPTER 12 ABBREVIATIONS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report